PatentsDB

Histone deacetylase inhibitors

US10301323B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10301323-B2
Application numberUS-201816046304-A
CountryUS
Kind codeB2
Filing dateJul 26, 2018
Priority dateFeb 28, 2011
Publication dateMay 28, 2019
Grant dateMay 28, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).

First claim

Opening claim text (preview).

We claim: 1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 2. The compound or salt of claim 1 , having a structure: 3. The compound or salt of claim 1 , having a structure: 4. The compound or salt of claim 1 , having a structure: 5. The compound or salt of claim 1 , having a structure: 6. The compound or salt of claim 1 , having a structure: 7. The compound or salt of claim 1 , having a structure: 8. The compound or salt of claim 1 , having a structure: 9. The compound or salt of claim 1 , having a structure: 10. The compound or salt of claim 1 , having a structure: 11. The compound or salt of claim 1 , having a structure: 12. The compound or salt of claim 1 , having a structure: 13. The compound or salt of claim 1 , having a structure: 14. The compound or salt of claim 1 , having a structure:

Assignees

Inventors

Classifications

  • A61P43/00

    Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • A61P37/00

    Drugs for immunological or allergic disorders · CPC title

  • A61P35/00

    Antineoplastic agents · CPC title

  • A61P31/12

    Antivirals · CPC title

  • A61P31/04

    Antibacterial agents · CPC title

Patent family

Related publications grouped by family.

View patent family 49622075

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10301323B2 cover?
This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
Who is the assignee on this patent?
Biomarin Pharm Inc
What technology area does this patent fall under?
Primary CPC classification C07D513/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).